Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections
- PMID: 10328575
- DOI: 10.1097/00002281-199905000-00004
Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections
Abstract
Most rheumatology textbooks lack adequate recommendations for specific immunization of patients with rheumatic diseases, especially those treated with immunosuppressive medications. The authors wish to alert clinicians to issues pertinent to immunization of immunosuppressed rheumatology patients. By elucidating deficiencies in the current literature, the authors hope to identify future directions for clinical investigation and to increase the rates of effective immunization against vaccine preventable diseases. In addition to focusing on immunizations, this article also discusses Pneumocystis carinii prophylaxis in immunosuppressed patients with rheumatic diseases and screening that clinicians should consider before beginning administration of immunosuppressive agents.
Similar articles
-
[Immunization in children and adolescents with rheumatic diseases].Z Rheumatol. 2007 Mar;66(2):111-2, 114-8, 120. doi: 10.1007/s00393-007-0150-z. Z Rheumatol. 2007. PMID: 17364157 Review. German.
-
Role of vaccinations and prophylaxis in rheumatic diseases.Best Pract Res Clin Rheumatol. 2015 Apr;29(2):306-18. doi: 10.1016/j.berh.2015.02.001. Epub 2015 Apr 2. Best Pract Res Clin Rheumatol. 2015. PMID: 26362746 Review.
-
Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.Semin Arthritis Rheum. 2019 Jun;48(6):1087-1092. doi: 10.1016/j.semarthrit.2018.10.018. Epub 2018 Nov 3. Semin Arthritis Rheum. 2019. PMID: 30449650 Free PMC article.
-
Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.Clin Exp Rheumatol. 2017 Jul-Aug;35(4):671-673. Epub 2017 Jan 27. Clin Exp Rheumatol. 2017. PMID: 28134084
-
[Pneumocystis pneumonia among patients with systemic diseases].Presse Med. 2009 Feb;38(2):251-9. doi: 10.1016/j.lpm.2008.11.004. Epub 2008 Dec 4. Presse Med. 2009. PMID: 19062243 French.
Cited by
-
Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.PLoS One. 2013 Nov 19;8(11):e78699. doi: 10.1371/journal.pone.0078699. eCollection 2013. PLoS One. 2013. PMID: 24260127 Free PMC article. Clinical Trial.
-
Acute Pneumocystis jirovecii Pneumonia Due to Absolute Lymphopenia.Cureus. 2022 Mar 2;14(3):e22768. doi: 10.7759/cureus.22768. eCollection 2022 Mar. Cureus. 2022. PMID: 35371839 Free PMC article.
-
[Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review].Z Rheumatol. 2006 Feb;65(1):18-20, 22-3. doi: 10.1007/s00393-005-0019-y. Z Rheumatol. 2006. PMID: 16421640 Review. German.
-
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.Clin Gastroenterol Hepatol. 2017 Jun;15(6):850-856. doi: 10.1016/j.cgh.2016.11.037. Epub 2016 Dec 21. Clin Gastroenterol Hepatol. 2017. PMID: 28013116 Free PMC article.
-
Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.Clin Microbiol Rev. 2004 Oct;17(4):770-82, table of contents. doi: 10.1128/CMR.17.4.770-782.2004. Clin Microbiol Rev. 2004. PMID: 15489347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical